```
=> d his

     (FILE 'HOME' ENTERED AT 14:52:14 ON 14 MAR 2000)

     FILE 'REGISTRY' ENTERED AT 14:52:29 ON 14 MAR 2000
               ACT BORS2/Q
               ---------
L1             STR
               ---------
               ACT BORIN237P/A
               ---------
L2             SCR 1166 AND 1705 AND 1996 AND 2014
L3             STR
L4           451 SEA FILE=REGISTRY SSS FUL L3 AND L2
               ---------
L5             STR L3
L6             0 S L5 SSS SAM SUB=L4
L7             STR L***
L8            10 S L7
L9            10 S L7 SSS SAM  SUB=L4
L10            STR L7
L11            6 S L10 SSS SAM SUB=L4
L12          152 S L10 SSS FUL SUB=L4   152 cpds - for dihydroxy+ether

     FILE 'CAPLUS' ENTERED AT 15:05:31 ON 14 MAR 2000
L13           14 S L12

     FILE 'REGISTRY' ENTERED AT 15:09:16 ON 14 MAR 2000
L14            STR L10
L15           0 S L14 SSS SAM SUB=L12
L16           5 S L14 SSS FUL SUB=L12   5 cpds

     FILE 'CAPLUS' ENTERED AT 15:12:24 ON 14 MAR 2000
L17           3 S L16   3 cites w/ dihydroxy R6
L18          11 S L13 NOT L17   11 cites w/ -->  O-R, O

     FILE 'CAOLD' ENTERED AT 15:18:22 ON 14 MAR 2000
L19           0 S L12   no cite

     FILE 'BEILSTEIN' ENTERED AT 15:18:47 ON 14 MAR 2000
L20           0 S L14 FULL   no cite

     FILE 'USPATFULL' ENTERED AT 15:19:21 ON 14 MAR 2000
L21           2 S L16
L22           2 S L12   2 cites for dihydroxy
L23           0 S L21 NOT L22

     FILE 'MARPAT' ENTERED AT 15:22:22 ON 14 MAR 2000
L24           7 S L14 FULL   7 cites

     FILE 'USPATFULL' ENTERED AT 15:24:07 ON 14 MAR 2000
               SET SMARTSELECT ON
L25         SEL L21 1- PN :       2 TERMS
               SET SMARTSELECT OFF
L26           2 S L25

     FILE 'MARPAT' ENTERED AT 15:24:24 ON 14 MAR 2000
L27           0 S L26
```

BORIN 09/308,237

6 C-OH

6 or more N

=> d que l13

L2 SCR 1166 AND 1705 AND 1996 AND 2014 → O ≥ 15

L3 STR



parent structure

one Oxygen can be bonded to anything

NODE ATTRIBUTES:
NSPEC IS R AT 8
NSPEC IS R AT 9
NSPEC IS R AT 13
NSPEC IS R AT 14
CONNECT IS E1 RC AT 24
CONNECT IS E1 RC AT 25
CONNECT IS E1 RC AT 28
CONNECT IS E1 RC AT 29
CONNECT IS E1 RC AT 30
CONNECT IS E1 RC AT 31
CONNECT IS E1 RC AT 50
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 48
DEFAULT ECLEVEL IS LIMITED

R = ring

RC = ring or chain

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 44

STEREO ATTRIBUTES: NONE
L4 451 SEA FILE=REGISTRY SSS FUL L3 AND L2

451 cpds

L10 STR

2 open oxygens

substructure 1



carbocyclic, unsat, monocyclic

Page 1-A

50

Page 2-A

```
NODE ATTRIBUTES:
NSPEC   IS R       AT   8
NSPEC   IS R       AT   9
NSPEC   IS R       AT  13
NSPEC   IS R       AT  14
CONNECT IS E1  RC AT  24
CONNECT IS E1  RC AT  25
CONNECT IS E1  RC AT  28
CONNECT IS E1  RC AT  29
CONNECT IS E1  RC AT  30
CONNECT IS E1  RC AT  31
CONNECT IS E1  RC AT  50
DEFAULT MLEVEL IS ATOM
GGCAT   IS MCY  UNS  AT  48
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  45

STEREO ATTRIBUTES: NONE
L12          152 SEA FILE=REGISTRY SUB=L4 SSS FUL L10
L13           14 SEA FILE=CAPLUS L12
```

152 cpds

=> d que l16

L2 SCR 1166 AND 1705 AND 1996 AND 2014
L3 STR

same parent as on p. 2



NODE ATTRIBUTES:
NSPEC IS R AT 8
NSPEC IS R AT 9
NSPEC IS R AT 13
NSPEC IS R AT 14
CONNECT IS E1 RC AT 24
CONNECT IS E1 RC AT 25
CONNECT IS E1 RC AT 28
CONNECT IS E1 RC AT 29
CONNECT IS E1 RC AT 30
CONNECT IS E1 RC AT 31
CONNECT IS E1 RC AT 50
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 48
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 44

STEREO ATTRIBUTES: NONE
L4 451 SEA FILE=REGISTRY SSS FUL L3 AND L2
L10 STR



same as substructure 1 on p 3

Page 1-A

O
50

Page 2-A
NODE ATTRIBUTES:
NSPEC IS R AT 8
NSPEC IS R AT 9
NSPEC IS R AT 13
NSPEC IS R AT 14
CONNECT IS E1 RC AT 24
CONNECT IS E1 RC AT 25
CONNECT IS E1 RC AT 28
CONNECT IS E1 RC AT 29
CONNECT IS E1 RC AT 30
CONNECT IS E1 RC AT 31
CONNECT IS E1 RC AT 50
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY UNS AT 48
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 45

STEREO ATTRIBUTES: NONE
L12 152 SEA FILE=REGISTRY SUB=L4 SSS FUL L10
L14 STR



Page 1-A

Page 2-A
NODE ATTRIBUTES:
NSPEC IS R AT 8
NSPEC IS R AT 9
NSPEC IS R AT 13
NSPEC IS R AT 14
CONNECT IS E1 RC AT 24
CONNECT IS E1 RC AT 25
CONNECT IS E1 RC AT 28
CONNECT IS E1 RC AT 29
CONNECT IS E1 RC AT 30
CONNECT IS E1 RC AT 31
CONNECT IS E1 RC AT 44
CONNECT IS E1 RC AT 50
CONNECT IS E1 RC AT 51
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY UNS AT 48
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 45

STEREO ATTRIBUTES: NONE
L16 5 SEA FILE=REGISTRY SUB=L12 SSS FUL L14 5 cpds

Substructure 2

same as substr 2 except the oxygens at 44 & 51 ~~can~~ both have a connectivity of 1 (they can only be bonded to 1C) they ~~other~~ can be bonded to H or nothing



=> d bib abs hitstr l21 1

L21 ANSWER 1 OF 2 USPATFULL
AN 97:112576 USPATFULL
TI Polypeptide compound and a process for preparation thereof
IN Ohki, Hidenori, Ikeda, Japan
Tomishima, Masaki, Minoo, Japan
Yamada, Akira, Fujiidera, Japan
Takasugi, Hisashi, Sakai, Japan
PA Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)
PI US 5693750 19971202
AI US 1996-675212 19960703 (8)
RLI Division of Ser. No. US 1994-242854, filed on 16 May 1994, now patented, Pat. No. US 5569646
PRAI GB 1993-10091 19930517
GB 1993-25269 19931210
DT Utility
EXNAM Primary Examiner: Davenport, Avis M.; Assistant Examiner: Harle, Jennifer
LREP Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1307
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process for preparing a polypeptide compound having antimicrobial activities of the following general formula: ##STR1## wherein R.sup.1 is hydrogen

R.sup.2 is acyl group,

R.sup.3 is hydroxy or acyloxy,

R.sup.4 is hydroxy or hydroxysulfonyloxy,

R.sup.5 is hydrogen or lower alkyl which may have one or more suitable substituent(s), and

R.sup.6 is hydrogen, hydroxy or acyl (lower) alkylthio and

a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **165727-74-2P**
(intermediate for prepn. of fungicidal cyclic peptide compds.)
RN 165727-74-2 USPATFULL
CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **165727-69-5 165727-74-2**
(reaction in prepn. of fungicidal cyclic peptide compds.)
RN 165727-69-5 USPATFULL
CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 165727-74-2 USPATFULL
CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



=> d bib abs hitstr l21 2

L21 ANSWER 2 OF 2 USPATFULL
AN 96:99198 USPATFULL
TI Polypeptide compound and a process for preparation thereof
IN Ohki, Hidenori, Ikeda, Japan
Tomishima, Masaki, Minoo, Japan
Yamada, Akira, Fujiidera, Japan
Takasugi, Hisashi, Sakai, Japan
PA Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)
PI US 5569646 19961029
AI US 1994-242854 19940516 (8)
PRAI GB 1993-10091 19930517
GB 1993-25269 19931210
DT Utility
EXNAM Primary Examiner: Weimar, Elizabeth C.; Assistant Examiner: Marshall, S. G.
LREP Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1305
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A polypeptide compound having antifungal activities of the following general formula: ##STR1## wherein R.sup.1 is hydrogen R.sup.2 is acyl group,

R.sup.3 is hydroxy or acyloxy,

R.sup.4 is hydroxy or hydroxysulfonyloxy,

R.sup.4 is hydrogen or lower alkyl which may have one or more suitable substituent(s), and

R.sup.6 is hydrogen, hydroxy or acyl (lower) alkylthio and a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **165727-74-2P**
(intermediate for prepn. of fungicidal cyclic peptide compds.)
RN 165727-74-2 USPATFULL
CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **165727-69-5 165727-74-2**
(reaction in prepn. of fungicidal cyclic peptide compds.)

RN 165727-69-5 USPATFULL

CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 165727-74-2 USPATFULL
CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

=> d bib ab qhit l24 1

L24 ANSWER 1 OF 7 MARPAT COPYRIGHT 2000 ACS
AN 131:144853 MARPAT
TI Cyclic hexapeptides having antimicrobial activity
IN Ohki, Hidenori; Murano, Kenji; Tojo, Takashi; Shiraishi, Nobuyuki; Matsuya, Takahiro; Matsuda, Hiroshi; Mizuno, Hiroaki; Barrett, David; Matsuda, Keiji; Kawabata, Kohji
PA Fujisawa Pharmaceutical Co., Ltd., Japan; et al.
SO PCT Int. Appl., 470 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9940108	A1	19990812	WO 1999-JP538	19990205
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9922998	A1	19990823	AU 1999-22998	19990205
PRAI	AU 1998-1728		19980209		
	AU 1998-3138		19980423		
	WO 1999-JP538		19990205		

AB Polypeptides I [R1 = H, (un)substituted arylaminoalkanoyl, aroyl, arylalkanoyl, or alkanoyl, amino protective group, heptylnaphthoyl, hexylnaphthoyl; R2 = H, OH; R3 = OH, hydroxysulfonyloxy, alkoxy; R4 = OH, alkoxy] or their salts were prepd. as antimicrobial activities (esp., antifungal activities). Thus, cyclic peptide II, prepd. via N-acylation using 4-[5-[4-(6-methoxyhexyloxy)phenyl]-1,3,4-thiadiazol-2-yl]benzoic acid benzotriazol-1-yl ester, showed MIC 0.0625 .mu.g/mL for inhibition of Candida albicans.

MSTR 3



G1 = 60

HN—G2
60

G2 = COPh (SR G11)
G9 = CH
G10 = OH
DER: or salts
MPL: claim 6

=> d bib ab qhit l24 2

L24 ANSWER 2 OF 7 MARPAT COPYRIGHT 2000 ACS
AN 131:45105 MARPAT
TI Preparation of Echinocandin B derivatives as antifungal agents
IN Courtin, Olivier; Fauveau, Patrick; Markus, Astrid; Melon Manguer, Dominique; Michel, Jean-Marc; Schio, Laurent
PA Hoechst Marion Roussel, Fr.
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9929716	A1	19990617	WO 1998-FR2671	19981209
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2772028	A1	19990611	FR 1997-15628	19971210
	AU 9915659	A1	19990628	AU 1999-15659	19981209

PRAI FR 1997-15628 19971210
FR 1998-13361 19981026
WO 1998-FR2671 19981209

AB The title compds. I (R1, R2 = H, OH, (substituted) alkyl, NR1 forms with the carbon bearing NR1R2 a double bond and R2 = MP; M = O, NH, alkylamino; P = H, (substituted) alkyl; R3 = H, OH, CH3; R4 = H, OH; R = linear or branched chain up to 30 carbon atoms optionally substituted with heteroatoms, aryls or heterocycles; T = H, CH3, CH2CONH2, CH2C.tplbond.N, (CH2)2NH2; Y = H, OH, halogen; W = H, OH; Z = H, CH3) were prepd. as antifungal agents (no data given). For example, 1-[(4R,5R)-4,5-dihydroxy-N2-(12-methyltetradecanoyl)-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandin B was treated with trimethylsilyl iodide and sodium thiosulfate in succession to give the intermediate 1-[N2-(12-methyltetradecanoyl)-4-oxo-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandin B in 62% yield. This intermediate, when treated with 2-(dimethylamino)ethylamine, gave the final product I [NR1R2 = NHCH2CH2NMe2, R = CO(CH2)10CH(CH3)CH2CH3, Z = CH3, W = Y = T = H, R3 = CH3, R4 = OH] as a mixt. of isomers, which were, then, sepd. via HPLC.

MSTR 4



G16 = 146



G20 = OH
G21 = OH
G23 = 126

DER: or salts
MPL: claim 22
NTE: additional heteroatom interruptions at alkyl in G16 also claimed

=> d bib ab qhit l24 3

L24 ANSWER 3 OF 7 MARPAT COPYRIGHT 2000 ACS
AN 129:54604 MARPAT
TI Cyclohexapeptides having antimicrobial activity
IN Ohki, Hidenori; Tomishima, Masaki; Yamada, Akira; Takasugi, Hisashi
PA Fujisawa Pharmaceutical Co., Ltd., Japan; Ohki, Hidenori; Tomishima, Masaki; Yamada, Akira; Takasugi, Hisashi
SO PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9823637	A1	19980604	WO 1997-JP4193	19971118
	W: CA, CN, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 941236	A1	19990915	EP 1997-912494	19971118
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				

PRAI AU 1996-3814 19961125
WO 1997-JP4193 19971118

AB Polypeptide compds. I [R1 = (un)substituted aroyl or alkanoyl; R2 = OH, HO3SO, alkoxy] or their salts were prepd. as antimicrobial agents. Thus, I [R1 = 4-[4-(4-hexyloxyphenyl)piperazin-1-yl]benzoyl, R2 = NaOSO2O] was prepd. by treating I [R1 = H, R2 = NaOSO2O] with 1-[4-[4-(4-hexyloxyphenyl)piperazin-1-yl]benzoyloxy]benzotriazole for 8 h in DMF contg. diisopropylethylamine.

MSTR 1

G28—G1

G1 = 66

C(O)-G2—G3
66 67

G2 = phenylene
G17 = OH
G28 = 64



DER: and salts or reactive derivatives
MPL: claim 1

NTE: also incorporates claim 10, structure III

=> d bib ab qhit l24 4

L24 ANSWER 4 OF 7 MARPAT COPYRIGHT 2000 ACS
AN 123:228903 MARPAT
TI Preparation of cyclic peptide compounds as .beta.-1,3-glucan synthase inhibitors and antimicrobial agents
IN Ohki, Hidenori; Tomishima, Masaki; Yamada, Akira; Takasugi, Hisashi
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO Can. Pat. Appl., 85 pp.
CODEN: CPXXEB
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2123921	AA	19941118	CA 1994-2123921	19940517
	AU 9461994	A1	19941124	AU 1994-61994	19940510
	AU 681119	B2	19970821		
	EP 644199	A1	19950322	EP 1994-107406	19940512
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1100104	A	19950315	CN 1994-105193	19940516
	ZA 9403356	A	19950328	ZA 1994-3356	19940516
	HU 68385	A2	19950628	HU 1994-1515	19940516
	US 5569646	A	19961029	US 1994-242854	19940516
	JP 06340693	A2	19941213	JP 1994-126977	19940517
	US 5693750	A	19971202	US 1996-675212	19960703
PRAI	GB 1993-10091		19930517		
	GB 1993-25269		19931210		
	US 1994-242854		19940516		

AB Cyclic peptide compds. [I; R1 = H; R2 = acyl; R3 = OH, acyloxy; R4 =HO, OSO3H; R5 = H or a lower alkyl group which is optionally substituted with a HO, acyl, di(lower)alkylamino or cyclic amino group; R6 = H, OH, or acyl-lower alkylthio] and pharmaceutically acceptable salts thereof, useful as fungicides for the treatment of Pneumocystis carinii infection, are prepd. Thus, 0.285 g NaBH3CN was added to a soln. of 1 g I (R1 = R3 = R6 = OH, R2 = Q, R4 = NaO3SO, R5 = H) in CF3CO2H contg. mol. sieves 4A and the resulting mixt. was stirred at ambient temp. for 1 h to give, after chromatog. by an ion-exchange column on DOWEX 50WX4 (Na+-type) and HPLC using a C18.mu. Bondpak resin, column chromatog. on ODS (YMC-gel ODS-AMS-50), and lyophilization, 318 mg I (R1 = R5 = H, R2 = Q, R3 = R6 = OH, R4 = NaO3SO) and 263 mg I (R1 = R5 = R6 = H, R2 = Q, R6 = OH, R4 = NaO3SO). I (R1 = R5 = H, R2 = Q1, R3 = R6 = OH, R4 = NaO3SO) showed IC50 of 0.05 .mu.g/mL against Candida albicans YU-1200.

MSTR 2



G1 = 66

66 C(O)—G8

G2 = OH
G3 = OH
G7 = OH
G8 = Ph (SO (1-3) G11)
DER: ~~of salts~~
MPL: claim 6

=> d bib ab qhit 124 5

L24 ANSWER 5 OF 7 MARPAT COPYRIGHT 2000 ACS
AN 123:112725 MARPAT
TI preparation of polypeptides as antimicrobials
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 47 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 06192292	A2	19940712	JP 1993-248668	19930909
PRAI GB 1992-19068		19920909		

AB Title compds. I [R1 = OH, alkoxy; R2 = OH; R3 = acyl; R4, R5 = OH; R6 = OH, alkanoyloxy; (un)protected carboxyalkoxy; R7 = OH, hydroxysulfonyloxy, (un)protected carboxyalkoxy; R8 = H, (un)substituted alkyl; R1R2 or R3R4 = O; R9, R10 = H, alkyl; with provisos] and their salts are prepd. Over 20 I were prepd. with data; however, no specific exptl. procedures are given for the prepn. of individual compds. I [R1 = R2 = R4 = R5 = R6 = R7 = R8 = OH, R3 = 6-(octyloxy)-2-naphthoyl, R8 = H] (also prepd.) had an IC50 of 0.2 .mu.g/mL against Candida albicans.

MSTR 1



G1 = OH
G2 = OH
G3 = 84

84 C(O)·G13

G4 = OH
G5 = OH
G7 = OH
G9 = OH
G13 = 96



DER: and salts
MPL: claim 1

=> d bib ab qhit 124 6

L24 ANSWER 6 OF 7 MARPAT COPYRIGHT 2000 ACS
AN 122:82078 MARPAT
TI Cyclic peptide antifungal agents and process for preparation thereof
IN Burkhardt, Frederick Joseph; Debono, Manuel; Nissen, Jeffrey Scott; Turner, William Wilson, Jr.
PA Lilly, Eli, and Co., USA
SO Eur. Pat. Appl., 56 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 561639	A1	19930922	EP 1993-302064	19930318
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CA 2091663	AA	19930920	CA 1993-2091663	19930315
	ZA 9301830	A	19940915	ZA 1993-1830	19930315
	NO 9300948	A	19930920	NO 1993-948	19930316
	BR 9301232	A	19930921	BR 1993-1232	19930318
	HU 63637	A2	19930928	HU 1993-785	19930318
	CN 1080926	A	19940119	CN 1993-103587	19930318
	CN 1036715	B	19971217		
	JP 06056892	A2	19940301	JP 1993-58529	19930318
	AU 9335341	A1	19930923	AU 1993-35341	19930319
	US 5965525	A	19991012	US 1995-449056	19950524
	AU 9665529	A1	19961205	AU 1996-65529	19960909
	AU 689391	B2	19980326		
	US 5932543	A	19990803	US 1997-873480	19970612

PRAI	US 1992-854117	19920319
	US 1992-992390	19921216
	US 1993-32228	19930317
	US 1995-449056	19950524

AB Title compds. (I; R, R11 = independently H, OH; R1 = H, OH, OSO3H; R2 = substituted PhCO, biphenylyl, naphthoyl, etc.; R7 = R1, phosphonooxy; R8 = H, Me, H2NCOCH2; R9, R10 = Me, H), were prepd. Thus, I (R = R7 = R11 = OH, R1 = H, R2 = Q1, R8 = R9 = R10 = Me), prepd. by enzymic deacylation and then reacylation of echinocandin B, showed ED50 = 0.84 mg/mL for controlling systemic fungal infections in mice. Several I were effective against Pneumocystis carinii in immunosuppressed rats. I in general exhibit oral bioavailability.

MSTR 1



G3 = OH

G4 = OH
G5 = OH
G6 = 63

63 C(O)-G7—G8

not hederoe

G7 = phenylene
DER: or pharmaceutically acceptable non-toxic salts
MPL: claim 2

=> d bib ab qhit l24 7

L24 ANSWER 7 OF 7 MARPAT COPYRIGHT 2000 ACS
AN 118:213544 MARPAT
TI Pharmaceutical composition against Pneumocystis carinii
IN Furuta, Takahisa; Iwamoto, Toshiro; Fujie, Akihiko; Nitta, Kumiko; Tsurumi, Yasuhisa; Shigematsu, Nobuharu; Kasahara, Chiyoshi; Hino, Motohiro; Okuhara, Masakuni
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO Eur. Pat. Appl., 69 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 486011	A2	19920520	EP 1991-119421	19911114
	EP 486011	A3	19920715		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 05000966	A2	19930108	JP 1991-354117	19911115
	US 1638	H1	19970304	US 1994-311434	19940926
PRAI	US 1990-614125	19901116			
	GB 1990-27152	19901214			
	GB 1991-1552	19910124			
	GB 1991-6822	19910402			
	US 1990-610759	19901108			
	US 1991-791926	19911115			

AB FR 901379 derivs. I (R1, R2 = H, acyl; R3 = H, OH, O3SOH; R4 = H, carbamoyl; R5, R6 = H, OH) were prepd. Thus, FR 901379 [I, R1 = CO(CH2)14Me, R2 = H, R3 = O3SOH, R4 = CONH2, R5, R6 = OH, II] was isolated from a culture of Coleophoma sp. F-11899 and deacylated with Actinoplanes utahensis to give II (R1 = H). Acylation of II (R1 = H) with 2,4,5-Cl3C6H2O2CC6H4O(CH2)7Me-4 gave II [R1 = COC6H4O(CH2)7Me-4] which at 2 mg/day i.p. in rats showed significant inhibition of P. carinii pneumocysts.

MSTR 1



NH-acyl on OH

G1 = 72

72 G6

G2 = OH
G3 = OH
G5 = OH
G6 = 90

90 C(O)-G22

G22 = Ph (SO)
DER: or pharmaceutically acceptable salts
MPL: claim 1
NTE: substitution is restricted

=> d bib abs hitstr l17 1

L17 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2000 ACS
AN 1998:388539 CAPLUS
DN 129:54604
TI Cyclohexapeptides having antimicrobial activity
IN Ohki, Hidenori; Tomishima, Masaki; Yamada, Akira; Takasugi, Hisashi
PA Fujisawa Pharmaceutical Co., Ltd., Japan; Ohki, Hidenori; Tomishima, Masaki; Yamada, Akira; Takasugi, Hisashi
SO PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9823637	A1	19980604	WO 1997-JP4193	19971118
W: CA, CN, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 941236	A1	19990915	EP 1997-912494	19971118
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
PRAI AU 1996-3814		19961125		
WO 1997-JP4193		19971118		

OS MARPAT 129:54604
GI



I

AB Polypeptide compds. I [R1 = (un)substituted aroyl or alkanoyl; R2 = OH, HO3SO, alkoxy] or their salts were prepd. as antimicrobial agents. Thus, I [R1 = 4-[4-(4-hexyloxyphenyl)piperazin-1-yl]benzoyl, R2 = NaOSO2O] was prepd. by treating I [R1 = H, R2 = NaOSO2O] with 1-[4-[4-(4-hexyloxyphenyl)piperazin-1-yl]benzoyloxy]benzotriazole for 8 h in DMF contg. diisopropylethylamine.
IT **208538-75-4 208538-76-5**
RL: RCT (Reactant)
(prepn. of cyclohexapeptides having antimicrobial activity)
RN 208538-75-4 CAPLUS
CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-4-[(4S)-4-(3,4-dihydroxyphenyl)-4-hydroxy-L-threonine]-5-[(3S)-3-hydroxy-L-glutamine]- (9CI) (CA INDEX NAME)

this case is WO

PAGE 1-A



PAGE 2-A



this case

RN 208538-76-5 CAPLUS
CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-4-[(4S)-4-(3,4-dihydroxyphenyl)-4-hydroxy-L-threonine]-5-[(3S)-3-hydroxy-L-glutamine]-, compd. with N,N-bis(1-methylethyl)-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 208538-75-4
CMF C56 H71 N9 O20

PAGE 1-A



PAGE 2-A



CM 2

CRN 3424-21-3
CMF C9 H21 N



=> d bib abs hitstr l17 2

L17 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2000 ACS
AN 1995:763519 CAPLUS
DN 123:228903
TI Preparation of cyclic peptide compounds as .beta.-1,3-glucan synthase inhibitors and antimicrobial agents
IN Ohki, Hidenori; Tomishima, Masaki; Yamada, Akira; Takasugi, Hisashi
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO Can. Pat. Appl., 85 pp.
CODEN: CPXXEB
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2123921	AA	19941118	CA 1994-2123921	19940517
	AU 9461994	A1	19941124	AU 1994-61994	19940510
	AU 681119	B2	19970821		
	EP 644199	A1	19950322	EP 1994-107406	19940512
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1100104	A	19950315	CN 1994-105193	19940516
	ZA 9403356	A	19950328	ZA 1994-3356	19940516
	HU 68385	A2	19950628	HU 1994-1515	19940516
	US 5569646	A	19961029	US 1994-242854	19940516
	JP 06340693	A2	19941213	JP 1994-126977	19940517
	US 5693750	A	19971202	US 1996-675212	19960703
PRAI	GB 1993-10091	19930517			
	GB 1993-25269	19931210			
	US 1994-242854	19940516			

OS MARPAT 123:228903
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Cyclic peptide compds. [I; R1 = H; R2 = acyl; R3 = OH, acyloxy; R4 =HO, OSO3H; R5 = H or a lower alkyl group which is optionally substituted with a HO, acyl, di(lower)alkylamino or cyclic amino group; R6 = H, OH, or acyl-lower alkylthio] and pharmaceutically acceptable salts thereof, useful as fungicides for the treatment of Pneumocystis carinii infection, are prepd. Thus, 0.285 g NaBH3CN was added to a soln. of 1 g I (R1 = R3 = R6 = OH, R2 = Q, R4 = NaO3SO, R5 = H) in CF3CO2H contg. mol. sieves 4A and the resulting mixt. was stirred at ambient temp. for 1 h to give, after chromatog. by an ion-exchange column on DOWEX 50WX4 (Na+-type) and HPLC using a C18.mu. Bondpak resin, column chromatog. on ODS (YMC-gel ODS-AMS-50), and lyophilization, 318 mg I (R1 = R5 = H, R2 = Q, R3 = R6 = OH, R4 = NaO3SO) and 263 mg I (R1 = R5 = R6 = H, R2 = Q, R6 = OH, R4 = NaO3SO). I (R1 = R5 = H, R2 = Q1, R3 = R6 = OH, R4 = NaO3SO) showed IC50 of 0.05 .mu.g/mL against Candida albicans YU-1200.

IT **165727-74-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(intermediate for prepn. of fungicidal cyclic peptide compds.)

RN 165727-74-2 CAPLUS
CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

IT **165727-69-5 165727-74-2**
RL: RCT (Reactant)
(reaction in prepn. of fungicidal cyclic peptide compds.)
RN 165727-69-5 CAPLUS
CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 165727-74-2 CAPLUS
CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

=> d bib abs hitstr l17 3

L17 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2000 ACS
AN 1995:716709 CAPLUS
DN 123:112725
TI preparation of polypeptides as antimicrobials
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 47 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 06192292	A2	19940712	JP 1993-248668	19930909
PRAI	GB 1992-19068		19920909		

OS MARPAT 123:112725
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = OH, alkoxy; R2 = OH; R3 = acyl; R4, R5 = OH; R6 = OH, alkanoyloxy; (un)protected carboxyalkoxy; R7 = OH, hydroxysulfonyloxy, (un)protected carboxyalkoxy; R8 = H, (un)substituted alkyl; R1R2 or R3R4 = Q; R9, R10 = H, alkyl; with provisos] and their salts are prepd. Over 20 I were prepd. with data; however, no specific exptl. procedures are given for the prepn. of individual compds. I [R1 = R2 = R4 = R5 = R6 = R7 = R8 = OH, R3 = 6-(octyloxy)-2-naphthoyl, R8 = H] (also prepd.) had an IC50 of 0.2 .mu.g/mL against Candida albicans.

IT **165727-74-2P 165727-80-0P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of polypeptides as antimicrobials)

RN 165727-74-2 CAPLUS
CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 165727-80-0 CAPLUS
CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]-5-[N-[(dimethylamino)methyl]-threo-3-hydroxy-L-glutamine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **165727-69-5**
RL: RCT (Reactant)
(reactant in prepn. of polypeptides as antimicrobials)
RN 165727-69-5 CAPLUS
CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 1-A



PAGE 2-A



● Na

RN 235114-39-3 CAPLUS
CN Pneumocandin A0, 1-[(4R,5R)-N2-[(4'-heptyl[1,1'-biphenyl]-4-yl)carbonyl]-4,5-dihydroxy-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 235114-41-7 CAPLUS
CN Pneumocandin A0, 1-[(4R,5R)-N2-[(4'-hexyl[1,1'-biphenyl]-4-yl)carbonyl]-4,5-dihydroxy-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 235114-42-8 CAPLUS
CN Pneumocandin A0, 1-[(4R,5R)-N2-[4-[4-[4-(hexyloxy)phenyl]-1-piperazinyl]benzoyl]-4,5-dihydroxy-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 235114-45-1 CAPLUS
CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-[4-[4-[(8-methoxyoctyl)oxy]phenyl]-1-piperazinyl]benzoyl]-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 235114-46-2 CAPLUS
CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-[4-[4-[(7-methoxyheptyl)oxy]phenyl]-1-piperazinyl]benzoyl]-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 235114-48-4 CAPLUS
CN Pneumocandin A0, 1-[(4R,5R)-N2-[4-[5-[4-(hexyloxy)phenyl]-1,3,4-thiadiazol-2-yl]benzoyl]-4,5-dihydroxy-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

IT **235108-74-4P 235108-75-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(cyclic hexapeptides having antimicrobial activity)

RN 235108-74-4 CAPLUS

CN Pneumocandin A0, 1-[(4R,5R)-N2-[4-[2-(4-butoxyphenyl)imidazo[2,1-b]-1,3,4-thiadiazol-6-yl]benzoyl]-4,5-dihydroxy-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 235108-75-5 CAPLUS
CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-[2-[4-(pentyloxy)phenyl]imidazo[2,1-b]-1,3,4-thiadiazol-6-yl]benzoyl]-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

=> d bib abs hitstr l18 3

L18 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2000 ACS
AN 1999:492332 CAPLUS
DN 131:269425
TI FK463, a novel water-soluble echinocandin lipopeptide: synthesis and antifungal activity
AU Tomishima, Masaki; Ohki, Hidenori; Yanada, Akira; Takasugi, Hisashi; Maki, Katsuyuki; Tawara, Shuichi; Tanaka, Hirokazu
CS Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co. Ltd., 2-1-6 Kashima Yodogawa-ku, Osaka, 532-8514, Japan
SO J. Antibiot. (1999), 52(7), 674-676
CODEN: JANTAJ; ISSN: 0021-8820
PB Japan Antibiotics Research Association
DT Journal
LA English
AB The novel water-sol. echinocandin lipopeptide FK463 (I) was prepd. by cycloaddn. reaction to give the key intermediate Me 4-(5-(4-pentyloxyphenyl)isoxazol-3-yl)benzoate (II) followed by II hydrolysis and condensation to yield the activated ester, and acylation of the activated ester with the cyclic peptide nucleus obtained by enzymic cleavage of the natural product FR901379. I exhibited broad-spectrum activity against clin. important pathogens including Aspergillus and azole-resistant and -susceptible Candida species; it had no activity against Cryptococcus neoformans.
IT **208538-73-2P**, FK463
RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and antifungal activity of the novel water-sol. echinocandin lipopeptide FK463)
RN 208538-73-2 CAPLUS
CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

=> d bib abs hitstr l18 4

L18 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2000 ACS
AN 1999:150173 CAPLUS
DN 131:13178
TI FK-463: Antifungal
AU Fromtling, Robert A.; Castaner, J.
CS Liaison-International, Merck Research Laboratories, Rahway, NJ, 07065-0900, USA
SO Drugs Future (1998), 23(12), 1273-1278
CODEN: DRFUD4; ISSN: 0377-8282
PB Prous Science
DT Journal; General Review
LA English
AB A review with 26 refs. FK-463 represents the latest lead in a novel chem. class of echinocandin-like lipopeptide antifungal compds. This agent has potent in vitro and exptl. in vivo activity against a variety of pathogenic Candida species (yeasts) and A. fumigatus (filamentous fungus). This compd. has favorable exptl. pharmacokinetics and a unique mode of action which makes it active against fungal isolates that are resistant to established antifungal agents particularly the triazole agent fluconazole. This new lead compd. is undergoing extensive preclin. evaluation in Japan to det. whether it may be a candidate for further development as a novel antifungal agent. Single-dose and initial multiple-dose phase I studies in normal human volunteers have been completed with the compd. being generally well tolerated. FK-463 has advanced to phase II clin. trials (26).
IT **208538-73-2**, FK 463
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(FK-463 as echinocandin-like lipopeptide antifungal compd. in humans and lab. animals)
RN 208538-73-2 CAPLUS
CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A





● Na

=> d bib abs hitstr l18 5

L18 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2000 ACS
AN 1998:352867 CAPLUS
DN 129:53437
TI Cyclic hexapeptides having antibiotic activity
IN Kanasaki, Ryuichi; Takase, Shigehiro; Hashimoto, Michizane; Hatanaka, Hiroshi; Sakamoto, Kazutoshi; Hashimoto, Seiji; Shiraishi, Nobuyuki; Ohki, Hidenori; Kawabata, Kohji
PA Fujisawa Pharmaceutical Co., Ltd., Japan; Kanasaki, Ryuichi; Takase, Shigehiro; Hashimoto, Michizane; Hatanaka, Hiroshi; Sakamoto, Kazutoshi; Hashimoto, Seiji; Shiraishi, Nobuyuki; Ohki, Hidenori; Kawabata, Kohji
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9822498	A1	19980528	WO 1997-JP4194	19971118
	W: CA, CN, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 941237	A1	19990915	EP 1997-912495	19971118
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
PRAI	AU 1996-3715		19961119		
	WO 1997-JP4194		19971118		

OS MARPAT 129:53437
GI



I

AB This invention relates to new polypeptide compds. (I: R1 = H or acyl) or a salt thereof, which have antimicrobial activities (esp., antifungal activities), inhibitory activity on .beta.-1,3-glucan synthase, to a process for prepn. thereof, to a pharmaceutical compn. comprising the same, and to a method for the prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal. Manuf. of I with Coleophoma sp. F-11899 by aerobic fermn. and chem. synthesis were shown. The physiol. and morphol. characteristics of Coleophoma sp. F-11899 were also given.

IT **208511-84-6P 208511-85-7P 208511-86-8P**
208511-88-0P 208511-89-1P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(cyclic hexapeptides having antibiotic activity)

RN 208511-84-6 CAPLUS

CN Proline, N2-[4-[4-[4-(hexyloxy)phenyl]-1-piperazinyl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-, (6.fwdarw.1)-lactam, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 208511-85-7 CAPLUS

CN Proline, N2-[4-[5-[4-(hexyloxy)phenyl]-1,3,4-thiadiazol-2-yl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-, (6.fwdarw.1)-lactam, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1 A



PAGE 2-A



● Na

RN 208511-86-8 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-, (6.fwdarw.1)-lactam, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 208511-88-0 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-, (6.fwdarw.1)-lactam, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 208511-89-1 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[[4''-(pentyloxy)[1,1':4',1''-terphenyl]-4-yl]carbonyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-, (6.fwdarw.1)-lactam, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

=> d bib abs hitstr l18 6

L18 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2000 ACS
AN 1998:47005 CAPLUS
DN 128:188328
TI Therapeutic effect of a water-soluble echinocandin compound on Pneumocystis pneumonia in animals
AU Furuta, Takahisa; Muramatsu, Hideyuki; Fujie, Akihiko; Fujihira, Shiro
CS Dept. Parasitology, Inst. Med. Sci., Univ. Tokyo, Tukuba, Japan
SO J. Eukaryotic Microbiol. (1997), 44(6), 53S
CODEN: JEMIED; ISSN: 1066-5234
PB Society of Protozoologists
DT Journal
LA English
AB Recently, it has been reported that a .beta.-1,3 -D-glucan synthesis inhibitor has growth inhibitory effects on fungi through inhibiting the synthesis of .beta.-1,3-glucan which is present in fungal cell walls. The inhibitor is also effective against Pneumocystis carinii infection because the cell wall of P. carinii cyst resembles that of the yeast Saccharomyces cerevisiae and contains high levels of .beta.-1,3-glucan. Since .beta.-1,3-glucan synthesis activity is not present in mammalian cells, it was thought that inhibition of the synthesis might be a good target to prevent the formation of P. carinii cysts and thus to selectively kill P. carinii in infected lung. Generally, however, the lipopeptide compds. so far reported as the .beta.-1,3-D - glucan inhibitor are hardly sol. in water. This insoly. limits their potential use as parenterally applicable agents and is one of the reason why they can not be developed for clin. use. We recently found that a strain of Coleophoma empetri F-11899 produces water-sol. echinocandin analogs, which have strong inhibitory effects on the growth of fungi. In this paper, we examd. the therapeutic effectiveness of a water-sol. echinocandin analog FR131535 on Pneumocystis pneumonia in immunodeficient animals. The results of this study indicate that the compd. is potentially useful for the treatment of Pneumocystis pneumonia.
IT **144371-87-9**, FR 131535
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pneumocystis pneumonia inhibition by echinocandin compd. FR131535)
RN 144371-87-9 CAPLUS
CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



=> d bib abs hitstr l18 7

L18 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2000 ACS
AN 1998:24752 CAPLUS
DN 128:175816
TI Therapeutic effects of water-soluble echinocandin compounds on Pneumocystis pneumonia in mice
AU Furuta, Takahisa; Muramatsu, Hideyuki; Fujie, Akihiko; Fujihira, Shiro; Abudullah, Noor Rain; Kojima, Somei
CS Department of Parasitology, The Institute of Medical Science, The University of Tokyo, Tokyo, 108, Japan
SO Antimicrob. Agents Chemother. (1998), 42(1), 37-39
CODEN: AMACCQ; ISSN: 0066-4804
PB American Society for Microbiology
DT Journal
LA English
AB The therapeutic effectiveness of water-sol. echinocandin compds. obtained from Coleophoma empetri F-11899, which has a strong inhibitory effect on the growth of fungi, was examd. in nude mice with exptl. Pneumocystis pneumonia. The studies demonstrated the potential usefulness of the compds.
IT **144371-87-9**, FR 131535
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(144371879; therapeutic effects of water-sol. echinocandin compds. on Pneumocystis pneumonia in mice)
RN 144371-87-9 CAPLUS
CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]- (9CI) (CA INDEX NAME)

PAGE 1-A




O—(CH2)7—Me

=> d bib abs hitstr l18 8

L18 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2000 ACS
AN 1996:462227 CAPLUS
DN 125:115150
TI Cyclic hexapeptides having antibiotic activity
IN Ohki, Hidenori; Tomishima, Masaki; Yamada, Akira; Takasugi, Hisashi
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 273 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9611210	A1	19960418	WO 1995-JP1983	19950929
	W: AU, CA, CN, FI, HU, JP, KR, MX, NO, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2202058	AA	19960418	CA 1995-2202058	19950929
	AU 9535780	A1	19960502	AU 1995-35780	19950929
	AU 696949	B2	19980924		
	EP 788511	A1	19970813	EP 1995-932935	19950929
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1168675	A	19971224	CN 1995-196643	19950929
	JP 10507174	T2	19980714	JP 1995-512472	19950929
	JP 2897427	B2	19990531		
	HU 77736	A2	19980728	HU 1998-338	19950929
	JP 10324695	A2	19981208	JP 1998-136756	19950929
	ZA 9508458	A	19960507	ZA 1995-8458	19951006
	BR 9504791	A	19961022	BR 1995-4791	19951006
	FI 9701397	A	19970527	FI 1997-1397	19970404
	NO 9701544	A	19970604	NO 1997-1544	19970404

PRAI GB 1994-20425 19941007
GB 1995-8745 19950428
JP 1996-512472 19950929
WO 1995-JP1983 19950929
OS MARPAT 125:115150
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to new cyclic polypeptide derivs. I [R1 = variety of substituted acyl groups] and their pharmaceutically acceptable salts. The compds. have antimicrobial activities (esp., antifungal activities) and inhibitory activity on .beta.-1,3-glucan synthase (no data), and are useful for prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g., P. carinii pneumonia). Examples include 124 compds. I, plus 346 precursor prepns. For instance, reaction of the precursor I.Na [R1 = H] with 1-[6-[(octyloxy)methyl]picolinoyl]benzotriazole 3-oxide in DMF in the presence of DMAP gave title compd. I [R1 = Q1]. In a test against Candida albicans FP-633 in vitro, I [R1 = Q2] had MIC of 0.2 .mu.g/mL.

IT **179165-46-9P 179165-47-0P 179165-53-8P**
179165-66-3P 179165-67-4P 179165-68-5P
179165-69-6P 179165-70-9P 179165-80-1P
179165-81-2P 179165-83-4P 179165-84-5P
179165-85-6P 179165-86-7P 179165-87-8P
179165-88-9P 179165-89-0P 179165-92-5P
179165-97-0P 179165-98-1P 179165-99-2P
179166-01-9P 179166-09-7P 179166-10-0P
179166-11-1P 179166-12-2P 179166-13-3P
179166-16-6P 179166-17-7P 179166-18-8P
179166-19-9P 179166-20-2P 179166-34-8P
179166-35-9P 179166-36-0P 179166-38-2P

179166-39-3P 179166-40-6P 179166-41-7P
179166-42-8P 179166-43-9P 179166-44-0P
179166-45-1P 179166-46-2P 179166-47-3P
179166-48-4P 179166-49-5P 179166-50-8P
179166-53-1P 179166-54-2P 179166-56-4P
179166-58-6P 179166-60-0P 179166-61-1P
179166-62-2P 179166-88-2P 179166-89-3P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of cyclic hexapeptides active against fungi and Pneumocystis carinii)

RN 179165-46-9 CAPLUS

CN Proline, 4,5-dihydroxy-N2-[4-[4-[4-(octyloxy)phenyl]-1-piperazinyl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, (6.fwdarw.1)-lactam, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179165-47-0 CAPLUS
CN Proline, 4,5-dihydroxy-N2 [[4'-[[8-(1H-1,2,4-triazol-1-yl)octyl]oxy][1,1'-biphenyl]-4-yl]carbonyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 179165-53-8 CAPLUS
CN Proline, N2-[3,4-bis(pentyloxy)benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179165-66-3 CAPLUS
CN Proline, N2-[(4'-hexyl[1,1'-biphenyl]-4-yl)carbonyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, (6.fwdarw.1)-lactam, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179165-67-4 CAPLUS
CN Proline, N2-[4-[4-[4-(hexyloxy)phenyl]-1-piperazinyl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, (6.fwdarw.1)-lactam, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179165-68-5 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[[4'-[(8-methoxyoctyl)oxy][1,1'-biphenyl]-4-yl]carbonyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179165-69-6 CAPLUS

CN Proline, 4,5-dihydroxy-N2-[[4'-(7-octenyloxy)[1,1'-biphenyl]-4-yl]carbonyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1 A



PAGE 2-A



● Na

RN 179165-70-9 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179165-80-1 CAPLUS
CN Proline, N2-[(4'-heptyl[1,1'-biphenyl]-4-yl)carbonyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, (6.fwdarw.1)-lactam, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179165-81-2 CAPLUS
CN Proline, N2-[4-[4-[4-[1,5-dihydro-1-(4-methylpentyl)-5-oxo-4H-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 179165-83-4 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[4-[4-[4-[(7-methoxyheptyl)oxy]phenyl]-1-piperazinyl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, (6.fwdarw.1)-lactam, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179165-84-5 CAPLUS
CN Proline, N2-[4-[4-[4-(6-heptenyloxy)phenyl]-1-piperazinyl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179165-85-6 CAPLUS
CN Proline, N2-[4-[4-[4-(heptyloxy)phenyl]-1-piperazinyl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179165-86-7 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[4-[4-[4-[(4-methylpentyl)oxy]phenyl]-1-piperazinyl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179165-87-8 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[4-[4-[4-(pentyloxy)phenyl]-1-piperazinyl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179165-88-9 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[[4'-[[8-(1H-tetrazol-1-yl)octyl]oxy][1,1'-biphenyl]-4-yl]carbonyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179165-89-0 CAPLUS

CN Proline, N2-[[4'-[[8-(2,6-dimethyl-4-morpholinyl)octyl]oxy][1,1'-biphenyl]-4-yl]carbonyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179165-92-5 CAPLUS
CN Proline, N2-[(4''-butoxy[1,1':4',1''-terphenyl]-4-yl)carbonyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179165-97-0 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[[4'-[(5-phenoxypentyl)oxy][1,1'-biphenyl]-4-yl]carbonyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179165-98-1 CAPLUS
CN Proline, N2-[4-[5-[4-(hexyloxy)phenyl]-1,3,4-oxadiazol-2-yl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179165-99-2 CAPLUS
CN Proline, N2-[4-[5-[4-(hexyloxy)phenyl]-1,3,4-thiadiazol-2-yl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, (6.fwdarw.1)-lactam, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-01-9 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-1H-pyrazol-3-yl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-09-7 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[4-[4-[4-[(8-methoxyoctyl)oxy]phenyl]-1-piperazinyl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, (6.fwdarw.1)-lactam, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-10-0 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[4-[4-[4-(7-octenyloxy)phenyl]-1-piperazinyl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-11-1 CAPLUS
CN Proline, N2-[3-fluoro-4-[4-[4-(hexyloxy)phenyl]-1-piperazinyl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-12-2 CAPLUS
CN Proline, N2-[3-chloro-4-[4-[4-(hexyloxy)phenyl]-1-piperazinyl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-13-3 CAPLUS
CN Proline, N2-(4-[1,4'-bipiperidin]-1'-ylbenzoyl)-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-16-6 CAPLUS
CN Proline, N2-[4-[4-(4-cyclohexylphenyl)-1-piperazinyl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-17-7 CAPLUS
CN Proline, N2-[4-[4-(4-hexylphenyl)-1-piperazinyl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-18-8 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[4-[4-(4-phenylcyclohexyl)-1-piperazinyl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-19-9 CAPLUS
CN Proline, N2-[4-[4-[1-[4-(hexyloxy)phenyl]-4-piperidinyl]-1-piperazinyl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-20-2 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[4-(4-pentylcyclohexyl)benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-34-8 CAPLUS
CN Proline, N2-[4-[5-[4-(hexyloxy)phenyl]-1H-pyrazol-3-yl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-35-9 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[[4''-[(6-methoxyhexyl)oxy][1,1':4',1''-terphenyl]-4-yl]carbonyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-36-0 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[4-[5-[4-[(8-methoxyoctyl)oxy]phenyl]-1,3,4-thiadiazol-2-yl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-38-2 CAPLUS
CN Proline, N2-[4-[5-(4-cyclohexylphenyl)-1,3,4-thiadiazol-2-yl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-39-3 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[4-[5-(4'-propoxy[1,1'-biphenyl]-4-yl)-1,3,4-oxadiazol-2-yl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-40-6 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[4-(5-nonyl-1,3,4-oxadiazol-2-yl)benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-41-7 CAPLUS
CN Proline, N2-[4-[3-[4-(hexyloxy)phenyl]-1,2,4-oxadiazol-5-yl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-42-8 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[4-[5-[4-(octyloxy)phenyl]-1,3,4-thiadiazol-2-yl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-43-9 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[4-[5-(4-pentylcyclohexyl)-1,3,4-thiadiazol-2-yl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-44-0 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[4-[3-[4-(pentyloxy)phenyl]-5-isoxazolyl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-45-1 CAPLUS

CN Proline, 4,5-dihydroxy-N2-[4-[5-[4-[(8-methoxyoctyl)oxy]phenyl]-1,3,4-oxadiazol-2-yl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-46-2 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[[4'-[(6-phenyl-3-pyridazinyl)oxy][1,1'-biphenyl]-4-yl]carbonyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-47-3 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[4-[5-[4-(octyloxy)phenyl]-1,3,4-oxadiazol-2-yl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-48-4 CAPLUS
CN Proline, N2-[4-[2-[4-(hexyloxy)phenyl]-4-pyrimidinyl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-49-5 CAPLUS
CN Proline, N2-[[4'-[[8-(2-ethoxyethoxy)octyl]oxy][1,1'-biphenyl]-4-yl]carbonyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-50-8 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[[4'-[[8-oxo-8-(1-piperidinyl)octyl]oxy][1,1'-biphenyl]-4-yl]carbonyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 179166-53-1 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[4-[5-(4'-propoxy[1,1'-biphenyl]-4-yl)-1,3,4-thiadiazol-2-yl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-54-2 CAPLUS
CN Proline, N2-[4-(1-heptyl-1H-pyrazol-4-yl)benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-56-4 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[(4'-pentyl[1,1'-biphenyl]-4-yl)carbonyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 179166-58-6 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[[4'-[[8-[(tetrahydro-2H-pyran-2-yl)oxy]octyl]oxy][1,1'-biphenyl]-4-yl]carbonyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 179166-60-0 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[[4'-[(6-propoxyhexyl)oxy][1,1'-biphenyl]-4-yl]carbonyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-61-1 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[[4''-[(5-methoxypentyl)oxy][1,1':4',1''-terphenyl]-4-yl]carbonyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-62-2 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[4-[5-[4-(1-piperidinyl)phenyl]-1,3,4-thiadiazol-2-yl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, (6.fwdarw.1)-lactam, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-88-2 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-1,3,4-thiadiazol-2-yl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 179166-89-3 CAPLUS
CN Proline, 4,5-dihydroxy-N2-[[4'-[[8-(2H-tetrazol-2-yl)octyl]oxy][1,1'-biphenyl]-4-yl]carbonyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1 A



PAGE 2-A



● Na

=> d bib abs hitstr l18 9

L18 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2000 ACS
AN 1994:164908 CAPLUS
DN 120:164908
TI Preparation of cyclic peptide derivatives as antibacterial agents
TN Oki, Hidetoku; Kawabata, Koji; Itane, Kazuo
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 21 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05202096	A2	19930810	JP 1992-291149	19921029

PRAI GB 1991-23046 19911030
OS MARPAT 120:164908
GI



I

AB N-acylcyclopeptides [I; M = H; R = C9-10 (1 or 2 halo-substituted)alkoxybenzoyl, (un)protected carboxybenzoyl, carboxy-higher alkoxy-benzoyl, lower alkoxyphenyl-benzoyl, hydroxy-higher alkoxyphenyl-benzoyl, lower alkenyloxyphenyl-benzoyl, C7 alkoxy-naphthoyl, (un)substituted aroylamino-lower alkanoyl, (un)substituted indolyl- or pyrazolyl-lower alkanoyl, steroid-contg. lower alkanoyl] or their salts are prepd. Thus, 0.393 g 4-dimethylaminopyridine was added to a soln. of 2.8 g 6-heptyloxy-2-naphthoic acid N-hydroxysuccinimide ester (prepn. given) and I (M = Na, R = H) in DMF and the soln. was stirred at room temp. for 12 h to give, after ion column chromatog. using Dowex-50WX4 and column chromatog. using ODS YMC-gel (ODS-AM S-50) (Yamamura Kagaku Kenkyusho Inc., Ltd.), 1.94 g I (M = Na, R = 6-heptyloxy-2-naphthoyl) (II). II showed min. inhibitory concn. of 0.1 .mu.g/mL against Candida albicans FP579. A total of 21 I (M = Na) were prepd.

IT **152868-86-5P 152868-87-6P 152868-88-7P**
152868-89-8P 152868-90-1P 152868-91-2P
152868-92-3P 152868-93-4P 152868-94-5P
152868-95-6P 152868-96-7P 152868-97-8P
152868-98-9P 152868-99-0P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of, as antibacterial agent)

RN 152868-86-5 CAPLUS

CN L-Proline, N2-[4-(decyloxy)benzoyl]-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 152868-87-6 CAPLUS

CN L-Proline, N2-[4-[(3,7-dimethyloctyl)oxy]benzoyl]-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 152868-88-7 CAPLUS
CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[4-[(nonadecafluorononyl)oxy]benzoyl]-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 152868-89-8 CAPLUS
CN L-Proline, N2-[4-[(3,7-dimethyloctyl)oxy]-3-fluorobenzoyl]-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 152868-90-1 CAPLUS
CN L-Proline, N2-[4-[(3,7-dimethyloctyl)oxy]-2,3,5,6-tetrafluorobenzoyl]-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 152868-91-2 CAPLUS
CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[4-[(octyloxy)carbonyl]benzoyl]-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 152868-92-3 CAPLUS
CN L-Proline, N2-[4-[(7-carboxyheptyl)oxy]benzoyl]-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 152868-93-4 CAPLUS
CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[[4'-(pentyloxy)[1,1'-biphenyl]-4-yl]carbonyl]-L-ornithine]-4-[(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 152868-94-5 CAPLUS
CN Pneumocandin A0, 1-[N2-[[4'-(hexyloxy)[1,1'-biphenyl]-4-yl]carbonyl]-(4R,5R)-4,5-dihydroxy-L-ornithine]-4-[(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 152868-95-6 CAPLUS
CN L-Proline, N2-[[4'-(2-hexenyloxy)[1,1'-biphenyl]-4-yl]carbonyl]-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, [1(E),6(2.alpha.,3.beta.,4.beta.)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 152868-96-7 CAPLUS
CN L-Proline, N2-[[4'-(5-hexenyloxy)[1,1'-biphenyl]-4-yl]carbonyl]-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 152868-97-8 CAPLUS
CN L-Proline, N2-[[4'-[(3,5-dimethyl-2,4-hexadienyl)oxy][1,1'-biphenyl]-4-yl]carbonyl]-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, [1(E),6(2.alpha.,3.beta.,4.beta.)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 152868-98-9 CAPLUS

CN L-Proline, N2-[[4'-[(3,7-dimethyl-2,6-octadienyl)oxy][1,1'-biphenyl]-4-yl]carbonyl]-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, [1(E),6(2.alpha.,3.beta.,4.beta.)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 152868-99-0 CAPLUS
CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[[4'-[(7-hydroxyheptyl)oxy][1,1'-biphenyl]-4-yl]carbonyl]-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

=> d bib abs hitstr l18 10

L18 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2000 ACS
AN 1993:213544 CAPLUS
DN 118:213544
TI Pharmaceutical composition against Pneumocystis carinii
IN Furuta, Takahisa; Iwamoto, Toshiro; Fujie, Akihiko; Nitta, Kumiko; Tsurumi, Yasuhisa; Shigematsu, Nobuharu; Kasahara, Chiyoshi; Hino, Motohiro; Okuhara, Masakuni
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO Eur. Pat. Appl., 69 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 486011	A2	19920520	EP 1991-119421	19911114
	EP 486011	A3	19920715		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 05000966	A2	19930108	JP 1991-354117	19911115
	US 1638	H1	19970304	US 1994-311434	19940926
PRAI	US 1990-614125	19901116			
	GB 1990-27152	19901214			
	GB 1991-1552	19910124			
	GB 1991-6822	19910402			
	US 1990-610759	19901108			
	US 1991-791926	19911115			

OS MARPAT 118:213544
GI



I

AB FR 901379 derivs. I (R1, R2 = H, acyl; R3 = H, OH, O3SOH; R4 = H, carbamoyl; R5, R6 = H, OH) were prepd. Thus, FR 901379 [I, R1 = CO(CH2)14Me, R2 = H, R3 = O3SOH, R4 = CONH2, R5, R6 = OH, II] was isolated from a culture of Coleophoma sp. F-11899 and deacylated with Actinoplanes utahensis to give II (R1 = H). Acylation of II (R1 = H) with 2,4,5-Cl3C6H2O2CC6H4O(CH2)7Me-4 gave II [R1 = COC6H4O(CH2)7Me-4] which at 2 mg/day i.p. in rats showed significant inhibition of P. carinii pneumocysts.

IT **144371-85-7P 144371-87-9P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and bactericidal activity of)

RN 144371-85-7 CAPLUS

CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 144371-87-9 CAPLUS

CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **141518-19-6P 141518-20-9P 141518-21-0P**
141518-22-1P 141518-23-2P 141518-24-3P
141518-34-5P 141518-35-6P 141518-36-7P
141518-53-8P 141518-54-9P 141537-12-4P
144313-04-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 141518-19-6 CAPLUS
CN L-Proline, N2-[4-(1,1-dimethylethyl)benzoyl]-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 141518-20-9 CAPLUS
CN L-Proline, N2-[4-(2-butoxyethoxy)benzoyl]-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 141518-21-0 CAPLUS
CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[4-(4-phenylbutoxy)benzoyl]-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 141518-22-1 CAPLUS
CN L-Proline, N2-[2-carboxy-4-(octyloxy)benzoyl]-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 141518-23-2 CAPLUS
CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[3-methoxy-4-(octyloxy)benzoyl]-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 141518-24-3 CAPLUS
CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[2,3,5,6-tetrafluoro-4-[(2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctyl)oxy]benzoyl]-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 141518-34-5 CAPLUS
CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-(4-octylbenzoyl)-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 141518-35-6 CAPLUS
CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[4-[4-(octyloxy)phenoxy]benzoyl]-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 141518-36-7 CAPLUS
CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[[4'-(octyloxy)[1,1'-biphenyl]-4-yl]carbonyl]-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 141518-53-8 CAPLUS
CN Pneumocandin A0, 1-[N2-[[4'-(heptyloxy)[1,1'-biphenyl]-4-yl]carbonyl]-(4R,5R)-4,5-dihydroxy-L-ornithine]-4-[(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 141518-54-9 CAPLUS
CN L-Proline, N2-[4-[4-(hexyloxy)phenoxy]benzoyl]-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 141537-12-4 CAPLUS
CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[2,3,5,6-tetrafluoro-4-[(2,2,3,3,4,4,5,5-octafluoropentyl)oxy]benzoyl]-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 144313-04-2 CAPLUS
CN L-Proline, N2-benzoyl-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxy-L-glutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



=> d bib abs hitstr l18 11

L18 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2000 ACS
AN 1992:449262 CAPLUS
DN 117:49262
TI Preparation of cyclic peptide (echinocandin B) antibiotics
IN Toshiro, Iwamoto; Akihiko, Fujie; Kumiko, Nitta; Yasuhisa, Tsurumi; Nobuharu, Shigematsu; Chiyoshi, Kasahara; Motohiro, Hino; Masakuni, Okuhara; Kazuo, Sakane; et al.
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO Eur. Pat. Appl., 69 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 462531	A2	19911227	EP 1991-109856	19910615
	EP 462531	A3	19921104		
	EP 462531	B1	19961002		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	FI 9102873	A	19911219	FI 1991-2873	19910614
	IL 98506	A1	19960912	IL 1991-98506	19910614
	EP 729974	A1	19960904	EP 1995-117638	19910615
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 143671	E	19961015	AT 1991-109856	19910615
	ES 2093658	T3	19970101	ES 1991-109856	19910615
	NO 9102347	A	19911219	NO 1991-2347	19910617
	CA 2044746	AA	19911219	CA 1991-2044746	19910617
	AU 9178435	A1	19920116	AU 1991-78435	19910617
	AU 651347	B2	19940721		
	HU 58108	A2	19920128	HU 1991-2014	19910617
	US 5376634	A	19941227	US 1991-715961	19910617
	CN 1059729	A	19920325	CN 1991-104847	19910618
	CN 1040541	B	19981104		
	ZA 9104677	A	19920429	ZA 1991-4677	19910618
	JP 04352799	A2	19921207	JP 1991-245284	19910618
	US 1638	H1	19970304	US 1994-311434	19940926
PRAI	GB 1990-13558	19900618			
	GB 1990-23666	19901031			
	GB 1991-1552	19910124			
	US 1990-610759	19901108			
	US 1990-614125	19901116			
	GB 1990-27152	19901214			
	GB 1991-6822	19910402			
	EP 1991-109856	19910615			
	US 1991-791926	19911115			

OS MARPAT 117:49262
GI



I

AB Title compds. (I; R1 = H, acyl; R2 = OH, acyloxy; R3 = H, HOSO2O; R4 = H, carbamoyl; with provisos that 1) R2 = acyloxy when R3 = H, and 2) R1 .noteq. palmitoyl when R2 = OH, R3 = HOSO2O, R4 = carbamoyl), were prepd. Thus, antibiotic FR901379 [I; R1 = Co(CH2)14Me, R2 = OH, R3 = OSO2Na, R4 = CONH2] (prepn. given) was fermented with Actinoplanes utahensis IFO-13244 to give N-deacylation and the product was acylated with 2,4,5-trichlorophenyl 4-octyloxybenzoate (prepn. given) to give I [R1 = COC6H4[O(CH2)7Me]-4, R2 = OH, R3 = OSO2ONa, R4 = CONH2] (II). II had IC50 = 0.31 (no units) against Candida albicans FP578. II at 500 mg/kg i.v. in mice was nontoxic.

IT **141518-07-2P 141518-19-6P 141518-20-9P**
141518-21-0P 141518-22-1P 141518-23-2P
141518-24-3P 141518-34-5P 141518-35-6P
141518-36-7P 141518-53-8P 141518-54-9P
141537-12-4P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of, as antibiotic)

RN 141518-07-2 CAPLUS

RN 141518-19-6 CAPLUS

CN L-Proline, N2-[4-(1,1-dimethylethyl)benzoyl]-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 141518-20-9 CAPLUS
CN L-Proline, N2-[4-(2-butoxyethoxy)benzoyl]-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 141518-21-0 CAPLUS
CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[4-(4-phenylbutoxy)benzoyl]-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 141518-22-1 CAPLUS
CN L-Proline, N2-[2-carboxy-4-(octyloxy)benzoyl]-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 141518-23-2 CAPLUS
CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[3-methoxy-4-(octyloxy)benzoyl]-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 141518-24-3 CAPLUS
CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[2,3,5,6-tetrafluoro-4-[(2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctyl)oxy]benzoyl]-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 141518-34-5 CAPLUS
CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-(4-octylbenzoyl)-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 141518-35-6 CAPLUS
CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[4-[4-(octyloxy)phenoxy]benzoyl]-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 141518-36-7 CAPLUS
CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[[4'-(octyloxy)[1,1'-biphenyl]-4-yl]carbonyl]-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 141518-53-8 CAPLUS
CN Pneumocandin A0, 1-[N2-[[4'-(heptyloxy)[1,1'-biphenyl]-4-yl]carbonyl]-(4R,5R)-4,5-dihydroxy-L-ornithine]-4-[(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 141518-54-9 CAPLUS
CN L-Proline, N2-[4-[4-(hexyloxy)phenoxy]benzoyl]-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 141537-12-4 CAPLUS
CN L-Proline, (4R,5R)-4,5-dihydroxy-N2-[2,3,5,6-tetrafluoro-4-[(2,2,3,3,4,4,5,5-octafluoropentyl)oxy]benzoyl]-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt, (2.alpha.,3.beta.,4.beta.)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

=> d bib abs hitstr l18 1

L18 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2000 ACS
AN 2000:11442 CAPLUS
DN 132:148942
TI In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi
AU Tawara, Shuichi; Ikeda, Fumiaki; Maki, Katsuyuki; Morishita, Yoshihiko; Otomo, Kazumi; Teratani, Noriko; Goto, Toshio; Tomishima, Masaki; Ohki, Hidenori; Yamada, Akira; Kawabata, Koji; Takasugi, Hisashi; Sakane, Kazuo; Tanaka, Hirokazu; Matsumoto, Fumio; Kuwahara, Shogo
CS Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, 532-8514, Japan
SO Antimicrob. Agents Chemother. (2000), 44(1), 57-62
CODEN: AMACCQ; ISSN: 0066-4804
PB American Society for Microbiology
DT Journal
LA English
AB The in vitro antifungal activity and spectrum of FK463 were compared with those of amphotericin B, fluconazole, and itraconazole by using a broth microdilution method specified by National Committee for Clin. Lab. Stds. document M27-A (National Committee for Clin. Lab. Stds., Wayne, Pa., 1997). FK463 exhibited broad-spectrum activity against clin. important pathogens including Candida species (MIC range, 0.0039 to 2 .mu.g/mL) and Aspergillus species (MIC range, 0.0039 to 0.0313 .mu.g/mL), and its MICs for such fungi were lower than those of the other antifungal agents tested. FK463 was also potently active against azole-resistant Candida albicans as well as azole-susceptible strains, and there was no cross-resistance with azoles. FK463 showed fungicidal activity against C. albicans, i.e., a 99% redn. in viability after a 24-h exposure at concns. above 0.0156 .mu.g/mL. The min. fungicidal concn. (MFC) assays indicated that FK463 was fungicidal against most isolates of Candida species. In contrast, the MFCs of FK463 for A. fumigatus isolates were much higher than the MICs, indicating that its action is fungistatic against this species. FK463 had no activity against Cryptococcus neoformans, Trichosporon species, or Fusarium solani. Neither the test medium (kind and pH) nor the inoculum size greatly affected the MICs of FK463, while the addn. of 4% human serum albumin increased the MICs for Candida species and A. fumigatus more than 32 times. Results from preclin. in vitro evaluations performed thus far indicate that FK463 should be a potent parenteral antifungal agent.
IT **208538-73-2**, FK463
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in vitro activities of the new lipopeptide antifungal agent FK463 against a variety of clin. important fungi)
RN 208538-73-2 CAPLUS
CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

=> d bib abs hitstr l18 2

L18 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2000 ACS
AN 1999:511176 CAPLUS
DN 131:144853
TI Cyclic hexapeptides having antimicrobial activity
IN Ohki, Hidenori; Murano, Kenji; Tojo, Takashi; Shiraishi, Nobuyuki; Matsuya, Takahiro; Matsuda, Hiroshi; Mizuno, Hiroaki; Barrett, David; Matsuda, Keiji; Kawabata, Kohji
PA Fujisawa Pharmaceutical Co., Ltd., Japan; et al.
SO PCT Int. Appl., 470 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9940108	A1	19990812	WO 1999-JP538	19990205
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9922998	A1	19990823	AU 1999-22998	19990205
PRAI	AU 1998-1728		19980209		
	AU 1998-3138		19980423		
	WO 1999-JP538		19990205		

OS MARPAT 131:144853
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Polypeptides I [R1 = H, (un)substituted arylaminoalkanoyl, aroyl, arylalkanoyl, or alkanoyl, amino protective group, heptylnaphthoyl, hexylnaphthoyl; R2 = H, OH; R3 = OH, hydroxysulfonyloxy, alkoxy; R4 = OH, alkoxy] or their salts were prepd. as antimicrobial activities (esp., antifungal activities). Thus, cyclic peptide II, prepd. via N-acylation using 4-[5-[4-(6-methoxyhexyloxy)phenyl]-1,3,4-thiadiazol-2-yl]benzoic acid benzotriazol-1-yl ester, showed MIC 0.0625 .mu.g/mL for inhibition of Candida albicans.

IT **235114-33-7P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(cyclic hexapeptides having antimicrobial activity)

RN 235114-33-7 CAPLUS
CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-, compd. with N-ethyl-N-(1-methylethyl)-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 235114-32-6
CMF C56 H71 N9 O23 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 7087-68-5
CMF C8 H19 N



IT **235114-36-0 235114-38-2 235114-39-3**
235114-41-7 235114-42-8 235114-45-1
235114-46-2 235114-48-4
RL: RCT (Reactant)
(cyclic hexapeptides having antimicrobial activity)

RN 235114-36-0 CAPLUS

CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-[5-[4-(1-piperidinyl)phenyl]-1,3,4-thiadiazol-2-yl]benzoyl]-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-, monosodium salt

(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 235114-38-2 CAPLUS
CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-[4-[4-(octyloxy)phenyl]-1-piperazinyl]benzoyl]-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-, monosodium salt (9CI) (CA INDEX NAME)